Study guide
13.1 Medication Management and Controlled Substances
Certified Hospice and Palliative Nurse CHPN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise
2 Chapter 2: Assessment, Goals, and Care Planning
2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions
3 Chapter 3: Life-Limiting Disease Progression I
3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression
4 Chapter 4: Disease Progression II and Imminent Death
4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death
5 Chapter 5: Pain Assessment
5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience
6 Chapter 6: Pharmacologic Pain Management
6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes
7 Chapter 7: Nonpharmacologic Pain and Opioid Safety
7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation
8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms
8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions
9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms
9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms
10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms
10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden
11 Chapter 11: Advance Care Planning, Benefits, and Safety
11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional
12 Chapter 12: Communication, Culture, and Psychosocial Support
12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation
13 Chapter 13: Caregiver Education and Medication Management
13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services
14 Chapter 14: Grief, Death, and End-of-Life Ethics
14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life
15 Chapter 15: Medicare Hospice Compliance and National Standards
15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines
16 Chapter 16: Legal, Professional Practice, Quality, and Policy
16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends
13.1 Medication Management and Controlled Substances
Key Takeaways Explain This Topic AI
Keep hospice opioids and benzodiazepines in a lockbox, count remaining doses with the nurse at visits, and never leave unlabeled syringes at the bedside.
The Prescription Drug Monitoring Program (PDMP) is a state controlled-substance database queried by the prescriber or an authorized delegate, not a family count sheet.
42 CFR 418.106 requires a written home controlled-drug policy given and discussed when those drugs are first ordered, with the discussion documented in the record.
FDA-aligned disposal prefers take-back; if unavailable, mix intact tablets with an unpalatable substance, and fold used fentanyl patches sticky-to-sticky then flush when labeling directs.
Opioid stewardship in hospice means lock, count, and dispose leftover morphine after death without undertreating dying pain or transferring bottles into the nurse's personal bag.
Last updated: August 2026
13.1 Medication Management and Controlled Substances
Hospice comfort care depends on controlled substances remaining in the correct bottle, at the ordered dose, in the hands of a designated caregiver. HPCC Domain 4 tests medication management, controlled substances, and medication safety as a teaching and systems job. The CHPN builds a home process that prevents diversion and accidental exposure without starving a dying person of morphine .
A household that fears "addiction" may hide tablets or skip nighttime oxycodone . A household with children, visitors, or a relative who uses substances may empty a bottle. Both fail the patient. Opioid stewardship at the end of life means lock, count, teach, and dispose — not undertreat dying pain.
Lockboxes, keys, and counting
Teach a single designated caregiver to keep morphine , oxycodone , hydromorphone , fentanyl transdermal patches, and lorazepam in a lockbox or locked cabinet, out of children's reach and out of casual visitor view. Concentrated oral morphine is often 20 mg/mL ; a teaspoon-range error is a hospital-level overdose. Do not store that bottle beside children's liquid acetaminophen or in an unlocked kitchen cabinet "so we can find it at 2 a.m." Keep the key with one named person. If several relatives rotate nights, teach a hand-off count at shift change, not a shared bowl of loose tablets on the dresser.
Count remaining tablets or milliliters with the nurse at visits. Document the count in the clinical record. Investigate shortages through the interdisciplinary group (IDG) rather than accepting "maybe we spilled it." Matching the count to the administration log is how you catch both honest mix-ups and diversion .
Do not leave unlabeled syringes of morphine on the nightstand. A labeled oral syringe with drug name, concentration, milligram dose, and time is a teaching tool. An unlabeled barrel is a dosing error waiting to happen and a theft target for anyone walking through the room.
PDMP — conceptually a prescriber tool
The Prescription Drug Monitoring Program (PDMP) is a state database of controlled-substance dispensing. The hospice prescriber — physician, nurse practitioner, or physician assistant — or an authorized delegate under state law queries it when writing or renewing oxycodone , morphine , or hydromorphone . The CHPN registered nurse is not the default PDMP user unless state law and agency policy name that nurse as a delegate. Exam options that treat the PDMP as a "family count sheet," a CMS recertification form, or a volunteer inventory are wrong. The RN's job is to report red flags — early refill requests, missing tablets, visitors handling the lockbox, liquid volume dropping faster than the order — to the prescriber and IDG so PDMP review and the plan of care can catch up.
Diversion without undertreating pain
Diversion clues include counts that do not match the record, a patient still writhing while the family insists "we gave everything," stories that change between relatives, and pressure to fill extra bottles "for the weekend." Respond with a non-shaming safety frame : more frequent counts, a lockbox, one key-holder, and IDG review. Do not lecture the dying person as an addict, and do not "solve" diversion by stopping analgesia. If a household cannot safely store opioids, the IDG considers more frequent RN visits , a different formulation (for example, patches that are harder to siphon than liquid), continuous home care during a crisis, or general inpatient care when the home is no longer a safe medication environment.
CMS disposal policy, witnessed waste, and leftover opioids after death
42 CFR 418.106 requires the hospice to have written policies for managing and disposing of controlled drugs in the patient's home . When controlled drugs are first ordered , the hospice must give a copy of that policy to the patient or representative and family, discuss it in a language and manner they understand, and document that the written policy was provided and discussed. In a hospice that provides inpatient care directly , disposal must also meet State and Federal requirements, with current records of receipt and disposition, and unused portions of a dose are typically wasted with two licensed nurses witnessing per facility policy.
In the home, a partial unused concentrated morphine dose is wasted per the same written policy — often with a family signature as witness when a second nurse is not present. Never pour leftover tablets down the sink "because it is easier" if policy and FDA labeling require a different method.
When expected death occurs at home, leftover oxycodone or morphine is both a child-poisoning risk and a street-diversion risk . Count remaining doses, document, and dispose that day per policy. The CHPN does not drop bottles into a personal bag or locked car to "return them to the pharmacy later" unless statute and policy specifically authorize chain-of-custody transfer. Family members do not keep leftover opioids "for a cousin's back pain."
FDA-aligned disposal
Preferred route: a DEA take-back kiosk , a scheduled take-back event, or a prepaid mail-back envelope . If take-back is not available and the medicine is not on the FDA flush list, mix intact tablets or liquid (do not crush pills) with an unpalatable substance — used coffee grounds, dirt, or cat litter — seal in a bag, and place in household trash. Scratch the name and prescription number off the empty labeled bottle. Do not mix tablets into applesauce, pudding, or other food that looks edible.
Some products — notably fentanyl transdermal patches — retain a lethal residual dose after use. FDA consumer guidance and product labeling direct: fold sticky sides together and flush used or leftover patches when a take-back option is not readily available. Do not put unfolded patches in household trash where a child or pet can find them. Do not cut patches to "make a smaller dose."
Product Storage Disposal when unused, used, or leftover after death
Morphine, oxycodone, or hydromorphone tablets or oral solution Lockbox; joint RN–caregiver count Take-back or mail-back first; else FDA trash mix with coffee grounds, dirt, or cat litter; do not crush
Fentanyl transdermal patch (used or leftover) Lockbox; never cut; never leave on furniture Fold sticky-to-sticky; flush when labeling/FDA flush list applies and take-back is not available
Lorazepam tablets Lockbox with other controlled drugs Take-back first; else unpalatable trash mix
Drawn morphine in a syringe Label drug, concentration, dose, and time; do not leave unlabeled Administer or waste per policy with a required witness; never leave unlabeled barrels
Empty prescription bottles — Scratch out name and Rx number before trash
Exam trap: Stewardship is lock and count so the next morphine dose can be given without fear — not so the dying person can be left in pain. Leftover opioids after death are disposed, not gifted, and not driven away in the nurse's car unless policy lawfully authorizes that transfer.